insights_auto
Zašto je 4142 pao 6,62%?
Istražite detaljnijechevron_right
4142:TPE
Adimmune Corp
14,80 TWD
arrow_downward
−6,62%(−1,05) 1D
20. stu, 13:30:09 GMT+8 · TWD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 4142...
Otvori
15,75 TWD
Najviša
15,75 TWD
Najniža
14,80 TWD
Trž. kap.
6,36 mlr.
Prosj. kol.
1,13 mil.
Količina
1,63 mil.
P/E omjer
85,76
52-tjed. najviša
21,50 TWD
52-tjed. najniža
14,80 TWD
EPS
0,17 TWD
Dionice u optjecaju
235,29 mil.
Broj djelatnika
564
Otvori
15,75 TWD
Najviša
15,75 TWD
Najniža
14,80 TWD
Trž. kap.
6,36 mlr.
Prosj. kol.
1,13 mil.
Količina
1,63 mil.
P/E omjer
85,76
52-tjed. najviša
21,50 TWD
52-tjed. najniža
14,80 TWD
EPS
0,17 TWD
Dionice u optjecaju
235,29 mil.
Broj djelatnika
564
Vijesti
Iz web-izvora i od partnera za vijesti
The Motley Fool
·
prije 1 sat
The S&P 500 and Dow Jones Are Dangerously Close to Joining the Nasdaq in a Correction. Here’s the Level That Would Put the Nasdaq in a Bear Market, and What History Says Investors Should Do During a Stock Market Crash.
24/7 Wall St.
·
prije 21 sat
His Indexed Annuity Tracks the S&P 500. The Fine Print Says "Price Return," Which Means It Leaves Out Every Dividend the 500 Companies Pay
WSJ
·
prije 2 dana
Dow, S&P 500 Poised to Close at a Correction
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp – informacije
Glavni izvršni direktor-
Zaposlenici564
Osnovano1965
Sjedište-
SektorHealth Care
Djelatnost-
Web-lokacijaadimmune.com.tw